Straits Times Index
3,336.59 +13.21 (+0.40%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.84 (+1.51%) Nasdaq
16,735.02 -2.06 (-0.01%) Bitcoin USD
68,107.27 +443.62 (+0.66%) CMC Crypto 200
1,430.30 +1.74 (+0.12%)
MRK Oct 2024 145.000 call
- Simply Wall St.
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
- Benzinga
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
- Reuters SG
Deals of the day-Mergers and acquisitions
** Prolific oil and gas developer Double Eagle is exploring a sale of its latest Permian Basin-based producer in a deal that could be worth more than $6.5 billion, including debt, according to people familiar with the matter. ** The owner of Britain's Royal Mail has agreed to a 3.57 billion pound ($4.55 billion) takeover by Czech billionaire Daniel Kretinsky, in a take-private deal of one of the world's oldest postal firms.
